Age (years)† | Sex (M/F) | FEV1 (% predicted)† | FVC (% predicted)† | FEV1/FVC (%)† | Methacholine PD20 (mg)‡ | |
---|---|---|---|---|---|---|
Data are presented as †mean (SD) and ‡geometric mean (range). | ||||||
Comparisons between asthmatic and control groups and between stable CF and control groups were performed using an unpaired t test. Within subject comparisons of spirometric measurements for the eight CF patients studied in exacerbation were undertaken with a paired t test. | ||||||
*p = 0.002 v control group; **p<0.001 v control group. | ||||||
Control (n = 15) | 39 (10) | 6/9 | 103 (15) | 107 (16) | 82 (5) | >1.5 |
Asthma (n = 12) | 38 (16) | 7/5 | 79 (18)** | 102 (16) | 66 (12) | 0.068 (<0.0256–1.3) |
CF stable (n = 18) | 24 (8)** | 11/7 | 68 (25)** | 88 (17)* | 65 (16)** | – |
CF exacerbation (n = 8) | 28 (9) | 4/4 | 58 (25) | 82 (20) | 59 (17) | – |